Title
Category
Credits
Event date
Cost
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
  • S.U.D
  • Women's Health
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • 1.00 AAFP Prescribed
$0.00
​Join Family Physician Rebecca Trotsky-Sirr and Sergeant Brian Gunsolley for a discussion of how patients are obtaining Fentanyl and other synthetic opioids and how physicians can help their patients recognize and understand the dangers of non-prescribed medication as well as encourage the use of reversal agents. In addition, resources will be provided to encourage more use of Medication Assisted Treatment.Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
$0.00
Dr. San Bartolome provides case studies and information about managing care for complex patients with addictions who use more than one substance (polysubstance use).Learning Objectives:At the end of this session, learners should be able to:Identify key safety considerations when treating complex, polysubstance use cases for MAT, andExplain 2 strategies for addressing complicated inductions involving methadone and fentanyl.
  • S.U.D
$0.00
This program will help overcome barriers to California providers wishing to begin offering Medication for Opioid Use Disorder (MOUD) and provide effective education to all interested family physicians. Patient-facing healthcare providers will learn to recognize OUD stigma, communicate more effectively, and be more confident in choosing MOUD.
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
$0.00
In this 19 minute presentation, Dr. Gloria Sanchez sheds light on critical and often neglected aspects of opioid use disorder (OUD) stigma encountered by health care professionals and people living with OUD. The medical model of addiction frames addiction as a treatable chronic medical condition rather than a personal failure. While Social Determinants of Health (SDOH) contribute to OUD stigma, we learn what steps providers can take to reduce the negative impacts of stigma and improve OUD care and outcomes.

Pages